

Validation of a PCR-Oligochromatography Test for Detection of *Trypanozoon* Parasites in a Multicenter Collaborative Trial[∇]

F. Claes,^{1,2*} S. Deborggraeve,² D. Verloo,³ P. Mertens,⁴ J. R. Crowther,⁵
T. Leclipteux,⁴ and P. Büscher²

Faculty of Bioscience Engineering, K. U. Leuven, Department of Biosystems, Kasteelpark Arenberg 30, 3001 Leuven, Belgium¹;
Department of Parasitology, Institute of Tropical Medicine, Antwerp, Belgium²; European Food Safety Authority,
Largo N. Palli 5/A, 43100 Parma, Italy³; Coris BioConcept, Gembloux, Belgium⁴; and
International Atomic Energy Agency, Wagramer Strasse 5, A-1400 Vienna, Austria⁵

Received 15 June 2007/Returned for modification 8 August 2007/Accepted 10 September 2007

A PCR-oligochromatography test for diagnosis of human and animal trypanosomiasis was evaluated through a multicenter ring trial with six laboratories testing a set of 21 blinded samples, resulting in qualitative data (positive or negative). Results showed an intralaboratory repeatability (accordance) of 88.7% (credible interval [CI], 84.4 to 92.5%) and an interlaboratory repeatability (concordance) of 88.1% (CI, 84.3 to 92.3%).

Recently, four antibody enzyme-linked immunosorbent assays (ELISAs) for animal trypanosomiasis (*Trypanosoma congolense* and *T. vivax*) were evaluated in a multicenter validation trial (5). Given that ELISAs generate quantitative data, modified Youden plots could be used to analyze the interlaboratory reproducibility of these assays. Unfortunately, this approach is unsuitable for the analysis of qualitative data (PCR, PCR-oligochromatography). For analyzing qualitative assays, different formulae were first described by Langton et al. (3) for a fixed number of laboratories and further modified for use in larger “population” trials by van der Voet and van Raamsdonk (6). Recently, these formulae were used to measure foot-and-mouth disease vaccine potency testing in cattle (2).

We developed a *Trypanozoon*-specific PCR-oligochromatography test of which the proof of principle is described by Deborggraeve et al. (1). In brief, *Trypanosoma brucei* 18S ribosomal DNA is amplified through PCR and amplicons are visualized on a dipstick through hybridization with a gold-conjugated probe (oligochromatography). Visualization is straightforward and takes only 5 min. Controls both for the PCR and for DNA migration are incorporated into the assay.

Before its adoption for diagnostic tests, we subjected it to a multicenter ring trial to evaluate its repeatability and reproducibility according to OIE (World Organization for Animal Health) validation criteria (4) and in accordance with the WHO/Special Programme for Research and Training in Tropical Diseases recommendation that “a multicenter validation of diagnostics based on molecular techniques (e.g., PCR) for epidemiological and clinical studies is strongly recommended” (7).

Six laboratories in Europe, Africa, and Asia (Belgium, Burkina-Faso, Germany, Kenya, Uganda, and Vietnam) participated in this multicenter trial, set up to evaluate the accordance (ACC; intralaboratory repeatability) and the concordance (CON;

interlaboratory reproducibility) of the *Trypanozoon* PCR-oligochromatography test.

A sample set consisting of positive (*T. brucei brucei* DNA) and negative (human DNA) controls and 21 blinded test samples was sent to all participating laboratories together with the necessary test reagents, a test report sheet, and a standard operating procedure following the protocol described by Deborggraeve et al. (1). Thus, the only obvious sources of variability between the laboratories are the manipulator, the micropipettes, the water bath, and the PCR thermocycler. Each laboratory received sufficient material to perform PCR-oligochromatography in triplicate on each sample. The blinded samples included a twofold serial dilution series of *T. brucei brucei* DNA (seven samples with concentrations ranging from 1,280 fg/μl to 2.5 fg/μl) and DNA at 100 ng/μl from the five taxa within *Trypanozoon* (*T. brucei brucei*, *T. brucei gambiense*, *T. brucei rhodesiense*, *T. evansi*, and *T. equiperdum*) and from nine non-*Trypanozoon* DNA samples (Table 1).

DNA was extracted using the QIAamp DNA minikit (QIAGEN, Germany) according to the manufacturer’s instructions and was quantified by Nanodrop (Isogen, Belgium).

Two main parameters were analyzed in casu: the ACC or intralaboratory repeatability, which is defined as the average chance of finding the same result for two identical DNA samples analyzed in the same laboratory under standard operating conditions (independently of whether the result is correct or not), and the CON or interlaboratory reproducibility, which is defined as the average chance of finding the same result for two identical samples analyzed in different laboratories under standardized conditions. As the interest is in the performance of the test on the samples in an arbitrary laboratory (not only the laboratories participating in this ring trial) the results of this multicenter trial were analyzed in a random framework (6), for which the formulae are as follows: $ACC_r = (1/L) \sum_i (p_{0,i}^2 + p_{1,i}^2)$ and $CON_r = P_0^2 + P_1^2$, in which $p_{0,i}^2$ and $p_{1,i}^2$ were defined as the squared proportion of PCR-oligochromatography-negative and -positive test results, respectively, for each analysis i and

* Corresponding author. Mailing address: Faculty of Bioscience Engineering, K. U. Leuven, Department of Biosystems, Kasteelpark Arenberg 30, 3001 Leuven, Belgium. Phone: 32 16 32 14 33. Fax: 32 16 32 19 94. E-mail: filip.claes@biw.kuleuven.be.

[∇] Published ahead of print on 19 September 2007.

TABLE 1. Triplicate results of *Trypanozoon* PCR-oligochromatography on a set of 23 DNA samples

Sample (amt [fg])	Expected result	No. of positive results (performed in triplicate) at laboratory:					
		1	2	3	4	5	6
<i>T. brucei brucei</i> AnTat 2.2	Positive	3	3	3	3	3	3
Human DNA	Negative	0	0	0	1	0	0
<i>T. brucei brucei</i> (2.5)	Positive	3	3	0	3	3	3
<i>T. brucei brucei</i> (5)	Positive	3	3	0	3	2	3
<i>T. brucei brucei</i> (10)	Positive	3	3	0	3	0	3
<i>T. brucei brucei</i> (20)	Positive	3	3	3	3	2	3
<i>T. brucei brucei</i> (80)	Positive	3	3	3	3	3	3
<i>T. brucei brucei</i> (320)	Positive	3	3	3	3	3	3
<i>T. brucei brucei</i> (1,280)	Positive	3	3	3	3	3	3
<i>T. brucei gambiense</i> LiTat 1.3	Positive	3	3	3	3	3	3
<i>T. brucei rhodesiense</i> AnTat 25.1	Positive	3	3	3	3	3	3
<i>T. evansi</i> RoTat 1.2	Positive	3	3	3	3	1	3
<i>T. equiperdum</i> OVI	Positive	3	3	3	3	3	3
<i>T. brucei gambiense</i> AnTat 9.1	Positive	3	3	3	1	0	3
<i>T. congolense</i> TRT 17	Negative	0	0	0	0	2	0
<i>T. vivax</i> ILRAD 700	Negative	0	0	0	0	0	2
<i>Theileria parva</i>	Negative	0	0	0	0	1	0
<i>Leishmania</i> sp.	Negative	0	0	0	0	2	0
<i>Plasmodium</i> sp.	Negative	0	0	0	0	3	2
<i>Schistosoma</i> sp.	Negative	0	0	0	1	0	0
Bovine DNA	Negative	0	0	0	0	0	1
<i>Trypanosoma cruzi</i>	Negative	0	0	0	0	3	0
<i>Trypanosoma rangeli</i>	Negative	0	0	0	0	3	0

where P_0^2 and P_1^2 were defined by the equations $P_0^2 = (1/L) \sum_{i=1}^L p_{0,i}$ and $P_1^2 = (1/L) \sum_{i=1}^L p_{1,i}$, with L the number of laboratories in the trial.

Uncertainty around $p_{0,i}$ and $p_{1,i}$ was quantified by Bayesian inference assuming that besides these data no other knowledge was available on the values of $p_{0,i}$ and $p_{1,i}$. The uncertainty distributions of the ACC and CON were obtained by repeatedly (in this case 5,000 times) drawing randomly from these posterior distributions followed by, at each iteration the calculation of ACC and CON according to the formulae described above. The histograms of all these ACC and CON values, calculated at each iteration, represent the uncertainty of the estimates. By using this Bayesian “simulation from posterior” approach one does not have to rely on asymptotic-normality assumptions to derive credible intervals (CI) around the estimates.

Statistical evaluation from the data set (Table 1), with 95% CI, gave the following results: an ACC of 88.7% (CI, 84.4 to 92.5%) and a CON of 88.1% (CI, 84.3 to 92.3%). These data and their distribution are presented in Fig. 1. Note that the results from laboratory 5 were excluded from this calculation due to multiple positive results in the negative-sample population, possibly due to cross-contamination or errors during test performance. Thus, the final analysis was performed on the data from the five remaining laboratories.

In this multicenter trial, the values for ACC and CON are high, indicating that this assay can be satisfactorily reproduced and applied in different laboratories.

As stated above the interest is in the performance of the test on the samples in an arbitrary laboratory (not only the laboratories participating in this ring trial); hence, ACC and CON are test-specific parameters. Uncertainty around these parameters can be reduced by increasing the sample size (the number of samples sent around). Sample sizes can be determined as a function of the minimal difference in ACC and CON that would likely be detected between different tests.

In four out of five laboratories, the PCR-oligochromatography assay could detect as low as 2.5 fg of DNA per PCR; laboratory 3 detected only 20 fg of DNA per reaction. This means that, in all laboratories evaluated, the assay can detect down to 1 parasite per reaction, since we assume that the genome of one trypanosome is 0.2 pg. The poor detection limit observed in laboratory 3 is probably due to the equipment used (thermocycler or calibration of pipettes) rather than the assay itself, since the repeatability of the results for the lower-quantity DNA samples is consistently negative in this laboratory.

The assay was developed to be *Trypanozoon* specific. Results from this trial show that this is indeed the case, except for some occasional false-positive results obtained in laboratories 4 and 6 (Table 1).

This is the first time that this statistical approach has been applied to evaluate the ACC and CON of a *Trypanozoon*-specific qualitative diagnostic assay. Results of this study show that (i) PCR-oligochromatography may serve as diagnostic test for human African trypanosomiasis and animal trypanosomiasis, alongside more-traditional diagnostic procedures, after further field evaluation and (ii) this statistical approach may be used in the future as a standard for multicenter trials to analyze other newly developed qualitative diagnostic tests.




FIG. 1. Distribution histograms for ACC (left) (intralaboratory “repeatability”) and CON (right) (interlaboratory “reproducibility”).

We acknowledge V. K. Nguyen, I. Sidibe, P.-H. Clausen, J. Enyaru, and J. Kinuya for their collaboration in this ring trial.

This study received financial support from the International Atomic Energy Agency (Vienna, Austria; contract number 12851/RBF). Filip Claes is a Postdoctoral Fellow of the Research Foundation Flanders.

REFERENCES

1. **Deborggraeve, S., F. Claes, T. Laurent, P. Mertens, T. Leclipteux, J. C. Dujardin, P. Herdewijn, and P. Büscher.** 2006. A molecular dipstick test for the diagnosis of sleeping sickness. *J. Clin. Microbiol.* **44**:2884–2889.
2. **Goris, N., P. Merkelbach-Peters, V. I. Diev, D. Verloo, V. M. Zakharov, H. P. Kraft, and K. De Clercq.** 2007. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences. *Vaccine* **25**:3373–3379.
3. **Langton, S. D., R. Chevenement, N. Nagelkerke, and B. Lombard.** 2002. Analysing collaborative trials for qualitative microbiological methods: accordance and concordance. *Int. J. Food Microbiol.* **79**:175–181.
4. **OIE.** 2002. Quality standard and guidelines for veterinary laboratories: infectious diseases. OIE Publications, Paris, France.
5. **Rebeski, D. E., E. M. Winger, J. O. Ouma, S. Kong Pages, P. Buscher, Y. Sanogo, R. H. Dwinger, and J. R. Crowther.** 2001. Charting methods to monitor the operational performance of ELISA method for the detection of antibodies against trypanosomes. *Vet. Parasitol.* **96**:11–50.
6. **van der Voet, H., and L. W. van Raamsdonk.** 2004. Estimation of accordance and concordance in interlaboratory trials of analytical methods with qualitative results. *Int. J. Food Microbiol.* **95**:31–234.
7. **WHO/Special Programme for Research and Training in Tropical Diseases.** 2001. Report of the Scientific Working Group Meeting on African Trypanosomiasis, 4 to 8 June 2001. WHO/Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland.